AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Vraylar (cariprazine) by Quarter
Vraylar (cariprazine) — International reported growth YoY (%) (%)
AbbVie Vraylar (cariprazine): 30.1% in Q2 2026, down 42.7 pts from a year earlier.
Latest, Q2 2026
30.1%
Period ended Jun 30, 2026
Change on a year earlier
-42.7 pts
72.8% in Q2 2025
History
9 quarters
Since Q2 2024
Sources
9
Documents cited below
Where the Q2 2026 figure comes from
“|| Vraylar | 1,068 | 3 | 1,071 | 18.9 | 30.1 | 18.9 | 28.5 | 18.9”
Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vraylar (cariprazine) — International reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 30.1% | -42.7 pts | Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 67.6% | +54.5 pts | Form 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | 21.7% | -4.1 pts | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 31.5% | -17.8 pts | Form 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗ |
| Q2 2025 | Jun 30, 2025 | 72.8% | +4.0 pts | Form 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗ |
| Q1 2025 | Mar 31, 2025 | 13.1% | – | Form 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗ |
| Q4 2024 | Dec 31, 2024 | 25.8% | – | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| Q3 2024 | Sep 30, 2024 | 49.3% | – | Form 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 68.8% | – | Form 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗ |
Cite this data
StockData. (2026). AbbVie Vraylar (cariprazine) (%), quarterly Q2 2024–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/vraylar-intl-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.